Introduction
============

In carcinoma of the oropharyngeal region, the area treated with radiation conventionally includes both cervical lymphatic chains, regardless of nodal involvement, because metastasis to the regional lymph nodes is reported frequently, even in clinically node-negative tumors \[[@b1-crt-2016-425],[@b2-crt-2016-425]\]. This extensive radiation-targeted volume contributes to favorable locoregional control in tonsil cancer but it may also lead to treatment-related morbidity, such as xerostomia, dysphagia, and mucositis. Permanent xerostomia is one of the most common and distressing complications after radiation treatment for head and neck cancer. Intensity-modulated radiotherapy (IMRT) is a good strategy for preventing xerostomia because the salivary glands can be spared \[[@b3-crt-2016-425]\]. Although IMRT reduces long-term severe xerostomia compared to three-dimensional conformal radiotherapy (3D-CRT), other sequelae, including the skin and mucosal toxicity, as well as low grade xerostomia can persist after IMRT \[[@b4-crt-2016-425],[@b5-crt-2016-425]\]. In addition, patients treated unilaterally achieve faster recovery and higher salivary function relative to the pretreatment levels than those treated bilaterally by IMRT \[[@b5-crt-2016-425],[@b6-crt-2016-425]\].

Several institutes have reported their experience of using a limited radiation field for patients with well-lateralized cancers of the tonsillar fossa to exclude treating the uninvolved contralateral neck; the contralateral regional recurrence rates were \< 6% \[[@b7-crt-2016-425]-[@b11-crt-2016-425]\]. These findings suggest that not all patients are likely to benefit from prophylactic radiation encompassing the contralateral neck. Recently, there is an increasing trend of younger patients with oropharyngeal cancer usually associated with the human papillomavirus (HPV) \[[@b12-crt-2016-425]\]. The treatment outcomes for HPV-related oropharyngeal cancer are superior to those of non-HPV--related disease \[[@b13-crt-2016-425],[@b14-crt-2016-425]\]. These evolving trends could also support a de-intensification strategy through a reduction of the radiation volume. Although the American College of Radiology provided recommendations for ipsilateral neck radiotherapy (INRT) based on published retrospective data, there are no reports comparing the survival outcomes and failure patterns between INRT and bilateral neck radiotherapy (BNRT).

This study analyzed retrospectively the clinical outcomes based on the radiotherapy (RT) area, for INRT versus BNRT, in patients who underwent a tonsillectomy for the treatment of tonsillar cancer who were matched using a propensity-scoring method. The investigation was a multi-institutional, retrospective study of the Korean Radiation Oncology Group, 11-07.

Materials and Methods
=====================

1. Patients
-----------

The medical records of patients with tonsillar carcinoma, who received a tonsillectomy followed by adjuvant RT between October 2001 and June 2012 at 16 institutes in Korea, were reviewed retrospectively. The eligibility criteria for the present study included (1) histologically confirmed squamous cell carcinoma in the tonsillar region, (2) non-distant metastatic disease status at diagnosis, (3) postoperative treatment with 3D-CRT or IMRT, (4) age ≥ 20 years, (5) Eastern Cooperative Oncology Group (ECOG) performance status 0-2, and (6) no previous radiation of the head and neck region. Of 390 patients, 149 were excluded from the analyses for the following reasons: advanced disease, which is classified as T3-4 or N3 (n=88); bilateral neck lymph nodes involvement (n=37); incomplete treatment (n=2); and insufficient data for analysis (n=22). Ultimately, 241 patients were included in the analysis.

Of these 241 patients, seventy patients were identified from each group (INRT and BNRT) by propensity score matching (PSM) based on their smoking history, chemotherapy, extranodal extension, T/N classification, and performance status. After PSM, the patients in each group were comparable in terms of the potential prognostic indicators. [Table 1](#t1-crt-2016-425){ref-type="table"} lists the patient characteristics before and after PSM. All patients underwent pretreatment workup comprising a physical examination, routine laboratory testing (complete blood count, liver function test), chest radiography, and neck magnetic resonance imaging or computed tomography. ^18^F-deoxyfluoroglucose positron emission tomography--computed tomography and neck ultrasonography were also applied when necessary.

2. Treatments
-------------

The extent and radiation dose were determined by the policies of each institution. The clinical target volume (CTV) was defined as follows: CTV1, primary tumor bed and the neck level of involved nodes; CTV2, adjacent neck level of involved nodes; and CTV3, elective region of the uninvolved neck. The planning target volume (PTV) was defined as the CTV plus 0.3-1.0 cm in all directions. For INRT, the median total doses applied to PTV1, PTV2, and PTV3 were 60.0 Gy (range, 54.0 to 70.0 Gy), 59.4 Gy (range, 36.0 to 70.0 Gy), and 45.0 Gy (range, 36.0 to 54.0 Gy), respectively, with a daily dose of 1.71 to 2.25 Gy. For BNRT, the median total doses applied to PTV1, PTV2, and PTV3 were 63.0 Gy (range, 50.0 to 72.0 Gy), 54.0 Gy (range, 27.0 to 66.0 Gy), and 50.0 Gy (range, 30.6 to 60.0 Gy), respectively, with a daily dose of 1.6-2.4 Gy. More patients in the BNRT group received IMRT than in the INRT group (31/70, 44.2% vs. 5/70, 7.1%, respectively). A neck dissection was performed in 59 (84.3%) and 55 (78.6%) patients in the INRT and BNRT groups, respectively. Chemotherapy was administered sequentially or concurrently with regimens, including cisplatin, carboplatin, or cetuximab.

3. Statistical analysis
-----------------------

The patients were allocated to either the INRT or BNRT group based on whether or not the radiation volume encompassed the uninvolved contralateral neck. The baseline characteristics of the patients were compared using chi-sqaure or Fisher exact tests. PSM was conducted by modeling the probability of the patients in both the INRT and BNRT groups. The probability of each individual patient was estimated using a logistic regression model based on their smoking history, administration of chemotherapy, extranodal extension, T/N classification, and ECOG performance status. The events of locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) were defined as locoregional recurrence, distant metastasis, any recurrence or death, and death, respectively. The survival rates were calculated from the initial date of treatment (tonsillectomy) to the date of each event or the last follow-up and were compared using the Kaplan-Meier method and log-rank test. The treatment-related toxicities were graded using the Radiation Therapy Oncology Group acute and late morbidity scoring system \[[@b15-crt-2016-425]\]. Acute toxicity was defined as occurring within 90 days of the initiation of treatment with toxicity considered late. The rates of toxicities in the two groups were compared using chi-square or Fisher exact tests. In all tests, p-values of \< 0.05 were considered significant.

Results
=======

1. Survival and patterns of failure
-----------------------------------

The median follow-up duration of the PSM population was 55 months (range, 3 to 133 months). The 5-year LRRFS (88.1% vs. 97.1%, p=0.083) and DFS (80.5% vs. 94.2%, p=0.085) rates were higher in the BNRT group than in the INRT group with borderline significance. No significant differences in the DMFS (92.7% vs. 97.0%, p=0.370) and OS (92.8% vs. 94.0%, p=0.985) were observed ([Fig. 1](#f1-crt-2016-425){ref-type="fig"}). [Fig. 2](#f2-crt-2016-425){ref-type="fig"} presents the patterns of failure. A total of 11 patients (15.7%) in the INRT group experienced recurrence, whereas only three patients (4.3%) experienced recurrence in the BNRT group. In the INRT group, three (4.3%) and one (1.4%) patient had isolated local and regional recurrence, respectively, three (4.3%) had locoregional recurrence, and four (5.7%) experienced distant recurrence. In the BNRT group, one patient each experienced local, distant, and regional with distant recurrences. Three patients (4.3%) and no patients had contralateral regional recurrence in the INRT and BNRT group, respectively, but the difference between the groups was not statistically significant (p=0.245). The three patients in the INRT group with contralateral regional recurrence included one with an isolated regional recurrence and two with regional combined with local recurrence.

In subgroup analysis, there were no contralateral neck recurrences in patients with T1-2N0-2a regardless of the treatment groups, INRT or BNRT. For patients with N2b, contralateral neck recurrence was more common in the INRT group than in the BNRT group (3/38 patients \[7.9%\] vs. 0/41 patients \[0.0%\], respectively), but the difference was not statistically significant (p=0.107). There was also a difference in the 5-year LRRFS (84.8% vs. 94.3%, p=0.234), but no statistical significance was identified. The 5-year OS (92.0% vs. 89.6%, p=0.750) was similar in the two groups after salvage treatment.

2. Toxicities
-------------

[Table 2](#t2-crt-2016-425){ref-type="table"} compares the acute and late toxicities occurring in patients in the INRT and BNRT groups. A statistically significant difference in the occurrence of grade ≥ 2 acute toxicities was observed between the INRT and BNRT groups (45.7% vs. 74.3%, p=0.001). Xerostomia was observed three times more frequently in the BNRT group than in the INRT group (38.6% vs. 12.9%, p=0.001), and severe oral mucositis (grade 3) was observed in 7.1% and 18.6% of patients in the INRT and BNRT groups, respectively (p=0.043). Among the late toxicities, 20 patients (28.6%) in the BNRT group suffered persistent xerostomia, compared to only three (4.3%) in the INRT group. No grade 3 toxicity was observed in either group, but six patients (8.6%) in the BNRT group experienced grade 2 dysphagia. The overall incidence of grade ≥ 2 late toxicities were 7.1% in INRT and 18.6% in BNRT (p \< 0.001).

3. Salvage treatment after locoregional recurrence
--------------------------------------------------

Nine patients experienced locoregional recurrence; five of them were salvaged successfully with surgery or combined treatment ([Table 3](#t3-crt-2016-425){ref-type="table"}). Two patients died of progressive disease, despite chemotherapy. No information on the treatment after recurrence was available for the remaining two patients because they were loss to follow-up.

Discussion
==========

Although current consensus recommendations \[[@b16-crt-2016-425]\] suggested bilateral prophylactic neck irradiation for N2b or more advanced disease, the data from a cohort of patients, \> 50% of whom had N2b disease, showed that INRT provides favorable outcomes with less RT-related toxicity in patients with tonsillar carcinoma. In this study, the 5-year LRRFS of patients receiving INRT was 88.1%, and contralateral neck recurrence was 4.3%. These results are similar to those reported in previous studies using INRT for the treatment of cancer of the tonsillar region \[[@b7-crt-2016-425]-[@b11-crt-2016-425]\]. As one of the largest series evaluating INRT for sparing the uninvolved contralateral neck, O'Sullivan et al. \[[@b11-crt-2016-425]\] reported that INRT resulted in a 3-year local control rate of 77% and 3.5% contralateral regional recurrence in 228 patients with carcinoma of the tonsillar region. In their study, six out of eight patients, whose primary lesion involved the palate or base of the tongue, showed contralateral neck failure, and they suggested that disease confined to the mucosa and with no more than 1 cm of medial extension could be treated safely by INRT. Since that report, several studies have supported INRT as an effective approach in selected patients without N3 disease. Chronowski et al. \[[@b8-crt-2016-425]\] reported excellent outcomes of INRT in a limited number of patients (n=102) with TX-2 and NX-2b with low rates of contralateral neck nodal relapse (2%) and perfect locoregional control (5-year rate 100%). Other studies including T3 disease also suggested favorable outcomes, and reported contralateral recurrence rates of 1%-6% and 5-year locoregional control of 90%-94% \[[@b7-crt-2016-425],[@b10-crt-2016-425]\].

Our data indicated a borderline significant difference in LRRFS between the INRT and BNRT groups in the PSM population (88.1% vs. 97.1%, p=0.083). In the BNRT group, local-regional recurrence occurred in two patients (one local and one regional and distant). In the INRT group, local-regional recurrence occurred in seven patients (three local, three local-regional, and one isolated contralateral). Of these six patients with local recurrence, two patients showed out-of-field local failure and the remaining four patients had in-field failure. The difference in LRRFS may be due to the difference in radiation modality, in which only five patients (7%) in the INRT group were treated with IMRT compared to 31 patients (44%) in the BNRT group. Delivering a homogeneous radiation dose to the target volumes including the cervical lymphatic area by 3D-CRT is an inherent challenge. McBride et al. \[[@b17-crt-2016-425]\] reported that better local control can be achieved using IMRT for the treatment of oropharyngeal cancer. They revealed a lower locoregional failure rate for IMRT compared to conventional RT (1.3% vs. 10.7%, p=0.017). The other advantage of IMRT includes its ability to deliver a higher dose to the target volume with a limited dose to the normal organs. In this study, the median prescribed dose in eight patients with locoregional recurrence (excluding one isolated contralateral regional recurrence among total nine patients) was 63 Gy (range, 60 to 66 Gy), which was similar to the 63 Gy (range, 50 to 72 Gy) in the BNRT group. The median PTV doses of four patients with in-field local failure in the INRT group were 60.0, 63.0, 63.0, and 64.8 Gy, respectively. Therefore, a higher local failure rate in the INRT group might have been related to other factors, such as the inhomogeneous dose distribution, rather than the prescription dose. Considering that the major pattern of failure was local recurrence in the INRT group, where 3D-CRT were used in the majority of patients, the wider adoption of IMRT in recent years may improve local control in patients treated with INRT.

The RT modality (3D-CRT vs. IMRT) could have been used as a variable for PSM to minimize bias. On the other hand, 3D-CRT was covered by the National Health Insurance in Korea during the period of this study, whereas IMRT was not. Therefore, 3D-CRT was used more often in relatively simple INRT, whereas IMRT was used more frequently for BNRT. Hence, there might be a discrepancy in the socio-economic status between the two groups, which could affect the clinical outcome. Considering that all potential unfavorable compounding factors were potentially more prevalent in the INRT group, the 5-year OS rate in this group was not inferior to that in the BNRT group (92.8% vs. 94.0%, p=0.985). This is partly due to the successful salvage treatment; of five patients receiving salvage treatment after locoregional recurrence in the INRT group, four (80%) achieved a complete response.

Subgroup analysis of the patients with N2b revealed considerable differences in the 5-year LRRFS (84.8% vs. 94.3%, p=0.234) and contralateral neck recurrence (7.9% vs. 0.0%, p=0.107) between the INRT and BNRT groups. If the analyses were performed with a larger cohort, it might have reached statistical significance. On the other hand, the risks of contralateral neck recurrence are still small (7.9%) with only one patient with an isolated contralateral neck, which was salvaged successfully by a surgical resection. Therefore, INRT for patients with N2b can still be offered cautiously for patients who are fit for BNRT.

A HPV infection is associated with favorable outcomes (locoregional control and survival) \[[@b13-crt-2016-425]\]. Unfortunately, information on the HPV infection status was limited to a small subset of patients in the present study (21/241, 9%); hence, the importance of HPV as a prognostic factor could not be assessed. In addition, the smoking history is an important prognostic indicator. The data contained a similar distribution of non-smokers between the both groups (INRT 51.4% vs. BNRT 47.1%, p=0.536).

Significant differences in the toxicities during or after RT were observed between the INRT and BNRT groups. The patients in the BNRT group were more likely to have persistent xerostomia and dysphagia compared to those in the INRT group, even though more patients in the BNRT group were treated with IMRT (INRT 7.1% vs. BNRT 44.2%). Only three patients (4%) in the INRT group experienced grade ≥ 2 xerostomia, whereas 20 patients (29%) in the BNRT group experienced this problem. Moreover, approximately 10% of patients receiving BNRT experienced grade 2 dysphagia, whereas none of the patients undergoing INRT did. The 3% rate of xerostomia in this population was modestly superior to that of the 8% reported by Dan et al. \[[@b18-crt-2016-425]\] who published the outcomes of INRT for node-positive tonsil cancer with a median follow-up of 37.2 months. IMRT is an advantageous option to reduce xerostomia when treating head and neck cancer because it facilitates the delivery of lower radiation doses to the parotid gland. Vergeer et al. \[[@b3-crt-2016-425]\] compared IMRT with 3D-CRT with regard to xerostomia in head and neck squamous cell carcinoma and reported that the mean dose to the parotid glands was reduced significantly (27 Gy vs. 43 Gy, p \< 0.001). Grade 2 xerostomia was observed less frequently in patients treated with IMRT than 3D-CRT (32% vs. 56%, p=0.002). The xerostomia rate of 32% after IMRT treatment was consistent with our finding of 29% in the BNRT group; however, it was considerably worse than the 4% of the patients observed in the INRT group. Jellema et al. \[[@b6-crt-2016-425]\], who evaluated RT-induced xerostomia by comparing INRT with BNRT in head and neck cancer, reported that the salivary function could be recovered to the baseline level by sparing the contralateral neck, being compensated for by hyperfunction of the contralateral parotid. Considering the findings from previous studies, exclusion of the uninvolved contralateral neck from the target volume is a more favorable strategy for maintaining the salivary function after treatment, even though the IMRT was adopted widely for the treatment of head and neck cancer.

The limitations of this study are related to its retrospective nature. INRT was compared with BNRT in terms of the locoregional control and survival in a population adjusted by PSM. Although the heterogeneous distribution of the clinical parameters that could influence the prognosis of patients was balanced after PSM, unknown confounding factors, such as physician selection bias regarding which patients received INRT, could remain.

In conclusion, given the data suggesting comparable outcomes with less toxicity, INRT is an attractive strategy in T1-2N0-2a patients with tonsillar carcinoma, compared to BNRT. For patients with N2b, there were small risks of contralateral neck recurrence when treated with INRT, but its impact on OS was limited with successful salvage treatment.
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![Comparison of the 5-year overall survival (OS) (A), disease-free survival (DFS) (B), locoregional relapse-free survival (LRRFS) (C), and distant metastasis-free survival (DMFS) (D) rates between the ipsilateral neck radiotherapy (INRT) and bilateral neck radiotherapy (BNRT) groups defined by propensity-score matching.](crt-2016-425f1){#f1-crt-2016-425}

![Patterns of failure in the ipsilateral neck radiotherapy (INRT) and bilateral neck radiotherapy (BNRT) groups defined by propensity-score matching. ^a)^Including two contralateral regional faliure, ^b)^Including one contralateral regional faliure.](crt-2016-425f2){#f2-crt-2016-425}

###### 

Patients' characteristics before and after propensity-score matching

  Characteristic                Total population   Propensity score-matched population                                                                                       
  ----------------------------- ------------------ ------------------------------------- --------------------------------------------------------- ------------ ------------ -------
  **Age (yr)**                                                                                                                                                               
   Median (range)               54 (31-76)         54 (32-81)                                                                                      55 (31-76)   55 (32-81)   
   \< 60                        58 (69.0)          113 (72.0)                            0.633                                                     48 (68.6)    50 (71.4)    0.712
   ≥ 60                         26 (31.0)          44 (28.0)                                                                                       22 (31.4)    20 (28.6)    
  **Sex**                                                                                                                                                                    
   Male                         73 (86.9)          141 (89.8)                            0.496                                                     61 (87.1)    62 (88.6)    0.796
   Female                       11 (13.1)          16 (10.2)                                                                                       9 (12.9)     8 (11.4)     
  **Histologic grade**                                                                                                                                                       
   WD                           14 (16.7)          17 (10.8)                             0.087                                                     9 (12.9)     5 (7.1)      0.348
   MD                           45 (53.6)          96 (61.1)                                                                                       39 (55.7)    45 (64.3)    
   PD                           17 (20.2)          39 (24.8)                                                                                       15 (21.4)    17 (24.3)    
   NA                           8 (9.5)            5 (3.2)                                                                                         7 (10.0)     3 (4.3)      
  **HPV**                                                                                                                                                                    
   (+)                          5 (6.0)            11 (7.0)                              0.526                                                     4 (5.7)      5 (7.1)      0.807
   (--)                         3 (3.6)            2 (1.3)                                                                                         3 (4.3)      1 (1.4)      
   NA                           76 (90.5)          144 (91.7)                                                                                      63 (90.0)    64 (91.4)    
  **Smoking**                                                                                                                                                                
   Never smoking                44 (52.4)          56 (35.7)                             0.010^[\*](#tfn1-crt-2016-425){ref-type="table-fn"}^      36 (51.4)    33 (47.1)    0.536
   Yes, but quit                19 (22.6)          27 (17.2)                                                                                       13 (18.6)    18 (25.7)    
   Current smoker               16 (19.0)          59 (37.6)                                                                                       16 (22.9)    17 (24.3)    
   NA                           5 (6.0)            15 (9.6)                                                                                        5 (7.1)      2 (2.9)      
  **Extracapsular extension**                                                                                                                                                
   (+)                          22 (26.2)          48 (30.6)                             0.766                                                     22 (48.6)    18 (25.7)    0.594
   (--)                         46 (54.8)          82 (52.2)                                                                                       34 (31.4)    40 (57.1)    
   NA                           16 (19.0)          27 (17.2)                                                                                       14 (20.0)    12 (17.1)    
  **T classification**                                                                                                                                                       
   1                            29 (34.5)          55 (35.0)                             0.937                                                     23 (32.9)    25 (35.7)    0.722
   2                            55 (65.5)          102 (65.0)                                                                                      47 (67.1)    45 (64.3)    
  **N classification**                                                                                                                                                       
   0                            20 (23.8)          14 (8.9)                              \< 0.001^[\*](#tfn1-crt-2016-425){ref-type="table-fn"}^   10 (14.3)    10 (14.3)    0.953
   1                            20 (23.8)          20 (12.7)                                                                                       16 (22.9)    14 (20.0)    
   2a                           6 (7.1)            11 (7.0)                                                                                        6 (8.6)      5 (7.1)      
   2b                           38 (45.2)          112 (71.3)                                                                                      38 (54.3)    41 (58.6)    
  **Staging**                                                                                                                                                                
   I                            5 (6.0)            1 (0.6)                               \< 0.001^[\*](#tfn1-crt-2016-425){ref-type="table-fn"}^   3 (4.3)      1 (1.4)      0.751
   II                           15 (17.9)          13 (8.3)                                                                                        7 (10.0)     9 (12.9)     
   III                          20 (23.8)          20 (12.7)                                                                                       16 (22.9)    14 (20.0)    
   IVA                          44 (52.4)          123 (78.3)                                                                                      44 (62.9)    46 (65.7)    
  **Chemotherapy**                                                                                                                                                           
   Yes                          18 (21.4)          50 (31.8)                             0.029^[\*](#tfn1-crt-2016-425){ref-type="table-fn"}^      17 (24.3)    18 (25.7)    0.845
   No                           66 (78.6)          107 (68.2)                                                                                      53 (75.7)    52 (74.3)    
  **ECOG PS**                                                                                                                                                                
   0                            18 (21.4)          60 (38.2)                             0.002^[\*](#tfn1-crt-2016-425){ref-type="table-fn"}^      18 (25.7)    15 (21.4)    0.803
   1                            64 (76.2)          83 (52.9)                                                                                       50 (71.4)    52 (74.3)    
   2                            0                  6 (3.8)                                                                                         0            0            
   NA                           2 (2.4)            8 (5.1)                                                                                         2 (2.9)      3 (4.3)      

Values are presented as number (%). INRT, ipsilateral neck radiotherapy; BNRT, bilateral neck radiotherapy; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; NA, not available; HPV, human papillomavirus; ECOG, Eastern Cooperative Oncology Group; PS, performance status.

Statistical significance (p \< 0.05).

Chi-square or Fisher exact test.

###### 

Acute and late toxicities of the patients treated with INRT and BNRT

  Toxicity          Grade^[a)](#tfn4-crt-2016-425){ref-type="table-fn"}^   INRT (n=70)   BNRT (n=70)   p-value^[b)](#tfn5-crt-2016-425){ref-type="table-fn"}^
  ----------------- ------------------------------------------------------ ------------- ------------- ---------------------------------------------------------
  **Acute**                                                                                            
   Xerostomia       0                                                      32 (45.7)     11 (15.7)     \< 0.001^[\*](#tfn3-crt-2016-425){ref-type="table-fn"}^
                    1                                                      29 (41.4)     32 (45.7)     
                    2                                                      8 (11.4)      25 (35.7)     
                    3                                                      1 (1.4)       2 (2.9)       
   Oral mucositis   0                                                      10 (14.3)     7 (10.0)      0.015^[\*](#tfn3-crt-2016-425){ref-type="table-fn"}^
                    1                                                      32 (45.7)     17 (24.3)     
                    2                                                      23 (32.9)     33 (47.1)     
                    3                                                      5 (7.1)       13 (18.6)     
  **Late**                                                                                             
   Xerostomia       0                                                      38 (54.3)     19 (27.1)     \< 0.001^[\*](#tfn3-crt-2016-425){ref-type="table-fn"}^
                    1                                                      29 (41.4)     31 (44.3)     
                    2                                                      3 (4.3)       18 (25.7)     
                    3                                                      0             2 (2.9)       
   Dysphagia                                                               61 (87.1)     49 (70.0)     0.008^[\*](#tfn3-crt-2016-425){ref-type="table-fn"}^
                    1                                                      9 (12.9)      15 (21.4)     
                    2                                                      0             6 (8.6)       

Values are presented as number (%). INRT, ipsilateral neck radiotherapy; BNRT, bilateral neck radiotherapy.

Statistical significance (p \< 0.05).

Radiation Therapy Oncology Group acute and late morbidity scoring criteria,

Chi-square or Fisher exact test.

###### 

Salvage treatment in patients with a locoregional recurrence (n=9)

  No   Sex/Age (yr)   Stage    CCRT   RT^[a)](#tfn6-crt-2016-425){ref-type="table-fn"}^   Total dose (Gy)   Location of recurrence           Time to recurrence (mo)   Treatment for recurrence   Last status
  ---- -------------- -------- ------ --------------------------------------------------- ----------------- -------------------------------- ------------------------- -------------------------- -------------
  1    M/52           cT2N0    N      INRT                                                64.8              Local                            7                         None                       NA
  2    M/54           cT2N2b   N      BNRT                                                60.0              Local                            3                         Surgery                    CR
  3    M/65           cT2N2a   N      INRT                                                66.0              Local                            27                        Surgery                    CR
  4    M/51           cT2N2b   Y      INRT                                                60.0              Local                            6                         Surgery                    CR
  5    M/51           cT2N2b   Y      INRT                                                60.0              Local+regional(contralateral)    20                        OP+reRT+CT                 CR
  6    M/47           cT2N2b   N      INRT                                                63.0              Local+regional (ipsilateral)     5                         CT                         PD
  7    M/78           cT1N2b   N      BNRT                                                63.0              Regional (ipsilateral)+distant   12                        CT                         PD
  8    M/53           cT2N2b   Y      INRT                                                63.0              Local+regional (bilateral)       51                        None                       NA
  9    M/67           cT2N2b   N      INRT                                                54.0              Regional (contralateral)         22                        Surgery                    CR

CCRT, concurrent chemoradiation; RT, radiotherapy; N, no; INRT, ipsilateral neck radiotherapy; NA, not available; BNRT, bilateral neck radiotherapy; CR, complete response; Y, yes; OP, operation; reRT, re-radiotherapy; CT, chemotherapy; PD, progressive disease.

All patients with locoregional recurrence were treated by three-dimensional conformal radiotherapy.

[^1]: Presented as an e-poster discussion session at the 2015 Annual Meeting of the American Society for Radiation Oncology, October 18-21, 2015, San Antonio, Texas, USA.
